Group 1 - DexCom, Inc. (NASDAQ:DXCM) is recognized as one of the best quality stocks to buy according to hedge funds, indicating significant upside potential [1] - TD Cowen maintains a buy rating and a price target of $100 for DexCom, citing the resolution of previous technical issues with the G7 continuous glucose monitoring (CGM) technology [2] - Analysts report that deployment and accuracy issues with the G7 system have largely been resolved, with no significant impact on market share, suggesting low competitive impact [3] Group 2 - Improvements made by DexCom's management have enhanced the reliability and functionality of the G7 system, supporting its sustained adoption and expansion in the global CGM market [4] - DexCom aims to create, develop, and market continuous glucose monitoring systems both domestically and internationally, reinforcing its position as a leading medical device company [5]